Value of monitoring activated clotting time when bivalirudin is used as the sole anticoagulation agent for percutaneous coronary intervention

Edouard Cheneau, Daniel Canos, Pramod K. Kuchulakanti, Seung-Woon Rha, Lowell F. Satler, William O. Suddath, Kenneth M. Kent, Augusto D. Pichard, Ron Waksman

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Anticoagulation during percutaneous coronary intervention (PCI) requires the monitoring of activated clotting time (ACT) to protect from periprocedural ischemic and bleeding complications; however, the optimal ACT values have not been established when PCI is performed with bivalirudin. After 495 consecutive patients treated for coronary artery disease with PCI received bivalirudin as a single anticoagulation agent, it was found that ACT is reproducible when bivalirudin is used during PCI and does not correlate with clinical events.

Original languageEnglish
Pages (from-to)789-792
Number of pages4
JournalAmerican Journal of Cardiology
Volume94
Issue number6
DOIs
Publication statusPublished - 2004 Sep 15
Externally publishedYes

Fingerprint

Percutaneous Coronary Intervention
Anticoagulants
Coronary Artery Disease
Hemorrhage
bivalirudin

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Value of monitoring activated clotting time when bivalirudin is used as the sole anticoagulation agent for percutaneous coronary intervention. / Cheneau, Edouard; Canos, Daniel; Kuchulakanti, Pramod K.; Rha, Seung-Woon; Satler, Lowell F.; Suddath, William O.; Kent, Kenneth M.; Pichard, Augusto D.; Waksman, Ron.

In: American Journal of Cardiology, Vol. 94, No. 6, 15.09.2004, p. 789-792.

Research output: Contribution to journalArticle

Cheneau, Edouard ; Canos, Daniel ; Kuchulakanti, Pramod K. ; Rha, Seung-Woon ; Satler, Lowell F. ; Suddath, William O. ; Kent, Kenneth M. ; Pichard, Augusto D. ; Waksman, Ron. / Value of monitoring activated clotting time when bivalirudin is used as the sole anticoagulation agent for percutaneous coronary intervention. In: American Journal of Cardiology. 2004 ; Vol. 94, No. 6. pp. 789-792.
@article{3994ea18d7c14820a21e02151d01b542,
title = "Value of monitoring activated clotting time when bivalirudin is used as the sole anticoagulation agent for percutaneous coronary intervention",
abstract = "Anticoagulation during percutaneous coronary intervention (PCI) requires the monitoring of activated clotting time (ACT) to protect from periprocedural ischemic and bleeding complications; however, the optimal ACT values have not been established when PCI is performed with bivalirudin. After 495 consecutive patients treated for coronary artery disease with PCI received bivalirudin as a single anticoagulation agent, it was found that ACT is reproducible when bivalirudin is used during PCI and does not correlate with clinical events.",
author = "Edouard Cheneau and Daniel Canos and Kuchulakanti, {Pramod K.} and Seung-Woon Rha and Satler, {Lowell F.} and Suddath, {William O.} and Kent, {Kenneth M.} and Pichard, {Augusto D.} and Ron Waksman",
year = "2004",
month = "9",
day = "15",
doi = "10.1016/j.amjcard.2004.05.068",
language = "English",
volume = "94",
pages = "789--792",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Value of monitoring activated clotting time when bivalirudin is used as the sole anticoagulation agent for percutaneous coronary intervention

AU - Cheneau, Edouard

AU - Canos, Daniel

AU - Kuchulakanti, Pramod K.

AU - Rha, Seung-Woon

AU - Satler, Lowell F.

AU - Suddath, William O.

AU - Kent, Kenneth M.

AU - Pichard, Augusto D.

AU - Waksman, Ron

PY - 2004/9/15

Y1 - 2004/9/15

N2 - Anticoagulation during percutaneous coronary intervention (PCI) requires the monitoring of activated clotting time (ACT) to protect from periprocedural ischemic and bleeding complications; however, the optimal ACT values have not been established when PCI is performed with bivalirudin. After 495 consecutive patients treated for coronary artery disease with PCI received bivalirudin as a single anticoagulation agent, it was found that ACT is reproducible when bivalirudin is used during PCI and does not correlate with clinical events.

AB - Anticoagulation during percutaneous coronary intervention (PCI) requires the monitoring of activated clotting time (ACT) to protect from periprocedural ischemic and bleeding complications; however, the optimal ACT values have not been established when PCI is performed with bivalirudin. After 495 consecutive patients treated for coronary artery disease with PCI received bivalirudin as a single anticoagulation agent, it was found that ACT is reproducible when bivalirudin is used during PCI and does not correlate with clinical events.

UR - http://www.scopus.com/inward/record.url?scp=4544241581&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4544241581&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2004.05.068

DO - 10.1016/j.amjcard.2004.05.068

M3 - Article

VL - 94

SP - 789

EP - 792

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 6

ER -